FDA Regulatory Affairs
FDA Office of Enforcement Acting Director Steven Niedelman will become assistant commissioner for regulatory affairs, a new position, as of Dec. 1. Niedelman has been acting head of enforcement since September, after joining the office as deputy director in July 2001 (1"The Pink Sheet" Sept. 16, p. 23). He previously spent 24 years in the Center for Devices & Radiologic Health's compliance office. Niedelman will continue to report to Associate Commissioner for Regulatory Affairs John Taylor...
You may also be interested in...
The FDA Office of Enforcement's transition to "risk-based" good manufacturing practices oversight will be led by an FDAer with more than two decades of experience in medical device manufacturing regulation
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.